Merck Releases 2021/2022 ESG Progress Report
The report details the company's efforts environmental, social, and governance areas.
Merck released its 2021/2022 Environmental, Social, and Governance (ESG) Progress Report, highlighting the company’s performance across four areas: access to health, employees, environmental sustainability, and ethics and values.
The report highlights several achievements in the ESG field from the past year. In the access to health category, the company noted that it committed 91.5 million doses of its HPV vaccines to Gavi-supported countries through 2025. Due to the expansion of manufacturing facilities, the company plans to double the supply of the vaccine in the coming years.
The report noted that Merck achieved greater-than 99% pay equity between male and female employees in 2021. This standard also occurred among diverse employees in equivalent positions, and this achievement is included in the employee section of the ESG report.
The report also notes that in the environmental sustainability section, Merck plans to achieve carbon neutrality by 2025. The company has already reduced greenhouse gas emissions in 2021 by 9% from a 2019 baseline. In the area of ethics and values, Merck notes that it has maintained 100% compliance with regulatory requirements for active incident monitoring, risk/harm analysis, and on-time notification of data breaches.
Merck’s full progress report can be read here.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
